Stevens-Johnson综合征/中毒性表皮坏死松解症:美国377例成人患者的多中心回顾性研究
该多中心回顾性研究纳入美国18个学术医学中心2000年1月1日至2015年6月1日期间377例成人SJS/TEN患者,最常见病因为药物反应(338/377,89.7%),最常见药物为甲氧苄啶/磺胺甲噁唑(89/338,26.3%)。基于第1天SCORTEN预测的院内死亡约77.7/368例(21%),实际观察死亡54/368例(14.7%),标准化死亡比=0.70(95%CI 0.58-0.79)。同时接受糖皮质激素和静脉注射免疫球蛋白者标准化死亡比最低(0.52,95%CI 0.21-0.79),但药物治疗的确切作用仍不明确,值得进一步研究。
要点
- 药物反应是SJS/TEN最常见病因(338/377,89.7%),甲氧苄啶/磺胺甲噁唑最常见(89/338,26.3%)。
- 观察死亡率14.7%(54/368)显著低于第1天SCORTEN预测的21%(77.7/368),标准化死亡比=0.70(95%CI 0.58-0.79)。
- 同时接受糖皮质激素和静脉注射免疫球蛋白者标准化死亡比最低(0.52,95%CI 0.21-0.79)。
核心结论
- 该大型队列提供了美国SJS/TEN患者的当代信息,死亡率虽高但显著低于预测值。
- 药物治疗的确切作用仍不明确,同时使用糖皮质激素和静脉注射免疫球蛋白等治疗值得进一步研究。
研究设计与样本
- 多中心回顾性研究,纳入美国18个学术医学中心住院会诊皮肤科医生诊治的SJS/TEN患者。
- 共纳入2000年1月1日至2015年6月1日期间377例成人SJS/TEN患者,其中260/377例(69%)来自2010年及以后。
主要发现
- 最常见病因为药物反应(338/377,89.7%),最常见为甲氧苄啶/磺胺甲噁唑(89/338,26.3%)。
- 多数患者收治于重症监护室(100/368,27.2%)或烧伤病房(151/368,41.0%)。
- 多数接受药物治疗(266/376,70.7%),其余仅支持治疗(110/376,29.3%);药物治疗者中常用糖皮质激素(113/266,42.5%)、静脉注射免疫球蛋白(94/266,35.3%)或两者联用(54/266,20.3%)。
- 基于第1天SCORTEN预测的院内死亡约77.7/368例(21%),观察死亡54/368例(14.7%),标准化死亡比=0.70(95%CI 0.58-0.79)。
- 按治疗分层,同时接受糖皮质激素和静脉注射免疫球蛋白者标准化死亡比最低(0.52,95%CI 0.21-0.79)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare, severe mucocutaneous reaction with few large cohorts reported. This multicenter retrospective study included patients with SJS/TEN seen by inpatient consultative dermatologists at 18 academic medical centers in the United States. A total of 377 adult patients with SJS/TEN between January 1, 2000 and June 1, 2015 were entered, including 260 of 377 (69%) from 2010 onward. The most frequent cause of SJS/TEN was medication reaction in 338 of 377 (89.7%), most often to trimethoprim/sulfamethoxazole (89/338; 26.3%). Most patients were managed in an intensive care (100/368; 27.2%) or burn unit (151/368; 41.0%). Most received pharmacologic therapy (266/376; 70.7%) versus supportive care alone (110/376; 29.3%)-typically corticosteroids (113/266; 42.5%), intravenous immunoglobulin (94/266; 35.3%), or both therapies (54/266; 20.3%). Based on day 1 SCORTEN predicted mortality, approximately 78 in-hospital deaths were expected (77.7/368; 21%), but the observed mortality of 54 patients (54/368; 14.7%) was significantly lower (standardized mortality ratio = 0.70; 95% confidence interval = 0.58-0.79). Stratified by therapy received, the standardized mortality ratio was lowest among those receiving both steroids and intravenous immunoglobulin (standardized mortality ratio = 0.52; 95% confidence interval 0.21-0.79). This large cohort provides contemporary information regarding US patients with SJS/TEN. Mortality, although substantial, was significantly lower than predicted. Although the precise role of pharmacotherapy remains unclear, co-administration of corticosteroids and intravenous immunoglobulin, among other therapies, may warrant further study.
引用
- Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J Invest Dermatol. 2018. PMID: 29758282. doi:10.1016/j.jid.2018.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。